ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2016

CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study.

Alexey Belogurov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.